1-lauryl-2-pyrrolidone, also known as laurocapram, is a synthetic compound belonging to the class of pyrrolidones. It is a colorless to pale yellow liquid with a characteristic odor. It is commonly used as a surfactant, emulsifier, and solubilizer in various applications, including personal care products, detergents, and industrial processes. 1-lauryl-2-pyrrolidone is synthesized through the reaction of lauric acid with pyrrolidone. Its amphiphilic nature allows it to effectively reduce surface tension and promote the formation of stable emulsions. The compound is studied for its potential applications in various fields, including cosmetics, pharmaceuticals, and agriculture. For instance, its surfactant properties make it suitable for use in shampoos, conditioners, and body washes. In pharmaceuticals, 1-lauryl-2-pyrrolidone can be used as a solubilizer for poorly soluble drugs, enhancing their bioavailability. Furthermore, its biocompatible nature allows it to be employed in various biological applications, such as cell culture and biomaterial development. Research on 1-lauryl-2-pyrrolidone focuses on optimizing its synthesis methods, exploring its potential applications in various fields, and assessing its safety and environmental impact.'
```
1-dodecylpyrrolidin-2-one : Pyrrolidin-2-one substituted at nitrogen by an n-dodecyl group.
ID Source | ID |
---|---|
PubMed CID | 62459 |
CHEMBL ID | 3186490 |
CHEBI ID | 146192 |
SCHEMBL ID | 43383 |
MeSH ID | M0179200 |
Synonym |
---|
1-dodecyl-2-pyrrolidone |
lauryl pyrrolidone |
n-dodecylpyrrolidinone |
1-dodecyl-2-pyrrolidinone |
2-pyrrolidinone, 1-dodecyl- |
1-lauryl-2-pyrrolidone |
brn 0155011 |
1-dodecyl-2-pyrrolidinone, 99% |
FT-0654021 |
FT-0652497 |
2687-96-9 |
n-(n-dodecyl)pyrrolidinone |
1-dodecylpyrrolidin-2-one |
n-lauryl-2-pyrrolidone |
CHEBI:146192 |
NCGC00248010-01 |
dtxsid4042206 , |
tox21_300374 |
cas-2687-96-9 |
dtxcid2022206 |
NCGC00254270-01 |
A818649 |
c16h31no |
ec 403-730-1 |
unii-3p14vw8fny |
3p14vw8fny , |
oristar lpl |
surfadone lp-300 |
laurylpyrrolidone |
lauryl pyrrolidone [inci] |
AKOS015898211 |
SCHEMBL43383 |
J-504832 |
n-dodecylpyrrolidin-2-one |
n-dodecyl-2-pyrrolidone |
NJPQAIBZIHNJDO-UHFFFAOYSA-N |
1-n-dodecylazacyclopentan-2-one |
CHEMBL3186490 |
mfcd00075066 |
CS-W012601 |
BS-16757 |
D70538 |
Q27257840 |
?1-lauryl-2-pyrrolidone |
Role | Description |
---|---|
epitope | The biological role played by a material entity when bound by a receptor of the adaptive immune system. Specific site on an antigen to which an antibody binds. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Class | Description |
---|---|
pyrrolidin-2-ones | A pyrrolidinone in which the oxo group is at position 2 of the pyrrolidine ring. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 44.7853 | 0.0072 | 15.7588 | 89.3584 | AID1224835 |
hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 54.9410 | 3.1890 | 29.8841 | 59.4836 | AID1224846 |
RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 19.3312 | 0.0060 | 38.0041 | 19,952.5996 | AID1159523 |
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 57.7648 | 0.0007 | 14.5928 | 83.7951 | AID1259368; AID1259392 |
AR protein | Homo sapiens (human) | Potency | 56.1831 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID743042 |
caspase 7, apoptosis-related cysteine protease | Homo sapiens (human) | Potency | 68.5896 | 0.0133 | 26.9810 | 70.7614 | AID1346978 |
estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 62.7583 | 0.0006 | 57.9133 | 22,387.1992 | AID1259377; AID1259378 |
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 29.7231 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
progesterone receptor | Homo sapiens (human) | Potency | 48.5577 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 54.9410 | 0.0002 | 14.3764 | 60.0339 | AID720691; AID720692; AID720719 |
retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 34.7757 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159553; AID1159555 |
estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 32.3166 | 0.0015 | 30.6073 | 15,848.9004 | AID1224848; AID1224849; AID1259401; AID1259403 |
farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 57.1756 | 0.3758 | 27.4851 | 61.6524 | AID743217; AID743220; AID743239 |
pregnane X nuclear receptor | Homo sapiens (human) | Potency | 27.3060 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 29.7448 | 0.0002 | 29.3054 | 16,493.5996 | AID743069; AID743075; AID743078; AID743079; AID743080; AID743091 |
peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 54.9410 | 0.0010 | 24.5048 | 61.6448 | AID743227 |
peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 47.1855 | 0.0010 | 19.4141 | 70.9645 | AID743140; AID743191 |
vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 27.4783 | 0.0237 | 23.2282 | 63.5986 | AID743223; AID743241 |
caspase-3 | Homo sapiens (human) | Potency | 68.5896 | 0.0133 | 26.9810 | 70.7614 | AID1346978 |
aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 53.0504 | 0.0007 | 23.0674 | 1,258.9301 | AID743085; AID743122 |
thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 57.6658 | 0.0016 | 28.0151 | 77.1139 | AID1224843; AID1259385; AID1259395 |
activating transcription factor 6 | Homo sapiens (human) | Potency | 61.6448 | 0.1434 | 27.6121 | 59.8106 | AID1159516 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 56.0157 | 19.7391 | 45.9784 | 64.9432 | AID1159509; AID1159518 |
v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 56.0157 | 0.0578 | 21.1097 | 61.2679 | AID1159526; AID1159528 |
thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 54.7229 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
heat shock protein beta-1 | Homo sapiens (human) | Potency | 37.2684 | 0.0420 | 27.3789 | 61.6448 | AID743210; AID743228 |
nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 68.5896 | 0.0006 | 27.2152 | 1,122.0200 | AID743202 |
Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 68.5896 | 0.0023 | 19.5956 | 74.0614 | AID651631; AID720552 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (50.00) | 18.2507 |
2000's | 3 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.41) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |